부산대학교 도서관

This document is a letter to the editor published in the Journal of Dermatological Treatment. It discusses the assessment of patient-reported outcomes (PROs) after 24 weeks of treatment with tralokinumab for atopic dermatitis (AD). AD is a chronic inflammatory skin condition that causes itching, skin lesions, and negatively affects one's quality of life. Tralokinumab is a high-affinity human monoclonal antibody that inhibits the binding of the IL-13 cytokine to its receptor. The study found that tralokinumab significantly improved PROs, including itch, sleep quality, overall quality of life, and mental health. However, the study had limitations, such as a small sample size and a short observation period, and further research is needed to assess tralokinumab's long-term effectiveness. [Extracted from the article]